| BUSINESSWEEK ONLINE : JULY 31, 2000 ISSUE | ||||||||
| ||||||||
 | ||||||||
| BUSINESSWEEK INVESTOR -- INSIDE WALL STREET
Don't Reject BioTransplant Although its products are still in early development, BioTransplant (BTRN) has been attracting big believers. This biotech's pharmaceuticals use technologies that reeducate the immune system to accept donor cells, tissues, and organs. ''There is an overwhelming need for a new approach in transplant-rejection therapy, which BTRN is well-positioned to deliver,'' says Joel Sendek, an analyst at Lazard Freres. He rates the stock, currently at 10, a buy, with a 12-month target of 19. ''With a powerful, potentially revolutionary technology that addresses the cancer and transplant markets--with partners MedImmune and Novartis--BioTransplant is in a good position,'' says Sendek. Its lead product, Medi-507, an antibody developed in partnership with MedImmune, ''could offer safety and superior efficacy for cancer therapy and organ transplants, and allow for the use of animal organs,'' says Sendek. He expects royalties by 2004, and profits in 2005. Sy Goldblatt, president of S2 Technology, an investment firm, says BioTransplant, with its ''extremely powerful technology, represents a compelling long-term investment opportunity.'' By GENE G. MARCIAL _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ BACK TO TOP |
|  |
 | |
RELATED ITEMS Don't Reject BioTransplant CHART: Still Beaten Down INTERACT E-Mail to Business Week Online | |||
|
Copyright 2000-2008, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use Privacy Notice  |